Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4

被引:10
作者
Mirandola, Leonardo [1 ,2 ,3 ,4 ]
Yu, Yuefei [1 ,2 ]
Jenkins, Marjorie R. [1 ,2 ,3 ,4 ,5 ,6 ]
Chiaramonte, Raffaella [1 ,2 ,7 ]
Cobos, Everardo [1 ,2 ,3 ,4 ]
John, Constance M. [8 ]
Chiriva-Internati, Maurizio [1 ,2 ,3 ,4 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Div Hematol & Oncol, Lubbock, TX 79430 USA
[2] SW Canc Treatment & Res Ctr, Lubbock, TX USA
[3] Texas Tech Univ, Hlth Sci Ctr, Laura W Bush Inst Womens Hlth, Amarillo, TX USA
[4] Texas Tech Univ, Hlth Sci Ctr, Ctr Womens Hlth & Gender Based Med, Amarillo, TX USA
[5] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Amarillo, TX USA
[6] Texas Tech Univ, Hlth Sci Ctr, Dept Obstet & Gynecol, Amarillo, TX USA
[7] Univ Milan, Dept Med Surg & Dent, Milan, Italy
[8] MandalMed Inc, San Francisco, CA USA
关键词
CANCER-TESTIS ANTIGEN; INHIBITS TUMOR-GROWTH; SPERM FIBROUS SHEATH; KAPPA-B ACTIVITY; BCL-X-L; BONE-MARROW; IN-VIVO; MURINE MODEL; IMPROVED SURVIVAL; PLASMA-CELLS;
D O I
10.1186/1471-2407-11-394
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Multiple myeloma (MM) is a fatal malignancy ranking second in prevalence among hematological tumors. Continuous efforts are being made to develop innovative and more effective treatments. The preclinical evaluation of new therapies relies on the use of murine models of the disease. Methods: Here we describe a new MM animal model in NOD-Rag1null IL2rgnull (NRG) mice that supports the engraftment of cell lines and primary MM cells that can be tracked with the tumor antigen, AKAP-4. Results: Human MM cell lines, U266 and H929, and primary MM cells were successfully engrafted in NRG mice after intravenous administration, and were found in the bone marrow, blood and spleen of tumor-challenged animals. The AKAP-4 expression pattern was similar to that of known MM markers, such as paraproteins, CD38 and CD45. Conclusions: We developed for the first time a murine model allowing for the growth of both MM cell lines and primary cells in multifocal sites, thus mimicking the disease seen in patients. Additionally, we validated the use of AKAP-4 antigen to track tumor growth in vivo and to specifically identify MM cells in mouse tissues. We expect that our model will significantly improve the pre-clinical evaluation of new anti-myeloma therapies.
引用
收藏
页数:11
相关论文
共 78 条
[1]  
Altekruse S F., SEER CANC STAT REV 1
[2]   Inhibition of bone-derived insulin-like growth factors toy a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse [J].
Araki, K ;
Sangai, T ;
Miyamoto, S ;
Maeda, H ;
Zhang, SC ;
Nakamura, M ;
Ishii, G ;
Hasebe, T ;
Kusaka, H ;
Akiyama, T ;
Tokuda, Y ;
Nagai, K ;
Minami, H ;
Ochiai, A .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (10) :2602-2608
[3]   Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis [J].
Asosingh, K ;
De Raeve, H ;
Van Riet, I ;
Van Camp, B ;
Vanderkerken, K .
BLOOD, 2003, 101 (08) :3136-3141
[4]   CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy [J].
Azab, Abdel Kareem ;
Runnels, Judith M. ;
Pitsillides, Costas ;
Moreau, Anne-Sophie ;
Azab, Feda ;
Leleu, Xavier ;
Jia, Xiaoying ;
Wright, Renee ;
Ospina, Beatriz ;
Carlson, Alicia L. ;
Alt, Clemens ;
Burwick, Nicholas ;
Roccaro, Aldo M. ;
Ngo, Hai T. ;
Farag, Mena ;
Melhem, Molly R. ;
Sacco, Antonio ;
Munshi, Nikhil C. ;
Hideshima, Teru ;
Rollins, Barrett J. ;
Anderson, Kenneth C. ;
Kung, Andrew L. ;
Lin, Charles P. ;
Ghobrial, Irene M. .
BLOOD, 2009, 113 (18) :4341-4351
[5]  
BANKERT RB, 2002, FRONT BIOSCI, V1, pC44
[6]   Treatment of multiple myeloma [J].
Barlogie, B ;
Shaughnessy, J ;
Tricot, G ;
Jacobson, J ;
Zangari, M ;
Anaissie, E ;
Walker, R ;
Crowley, J .
BLOOD, 2004, 103 (01) :20-32
[7]   A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6 [J].
Baughn, Linda B. ;
Di Liberto, Maurizio ;
Wu, Kaida ;
Toogood, Peter L. ;
Louie, Tracey ;
Gottschalk, Rachel ;
Niesvizky, Ruben ;
Cho, Hearn ;
Ely, Scott ;
Moore, Malcolm A. S. ;
Chen-Kiang, Selina .
CANCER RESEARCH, 2006, 66 (15) :7661-7667
[8]   Extravasation and homing mechanisms in multiple myeloma [J].
Broek, Isabelle Vande ;
Vanderkerken, Karin ;
Van Camp, Benjamin ;
Van Riet, Ivan .
CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 (04) :325-334
[9]   Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis [J].
Bueno, Clara ;
Lopes, Luiz F. ;
Greaves, Mel ;
Menendez, Pablo .
EXPERIMENTAL HEMATOLOGY, 2007, 35 (10) :1477-1478
[10]   Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid [J].
Campbell, Richard A. ;
Sanchez, Eric ;
Steinberg, Jeffrey A. ;
Baritaki, Stavroula ;
Gordon, Melinda ;
Wang, Cathy ;
Shalitin, Dror ;
Chen, Haiming ;
Pang, Shen ;
Bonavida, Benjamin ;
Said, Jonathan ;
Berenson, James R. .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) :467-478